A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pathologically confirmed HER2-positive MBC
Progression of or new brain metastases after completion of whole-brain radiotherapy or stereotactic radiosurgery
Completion of whole-brain radiotherapy or stereotactic radiosurgery more than 60 days prior to enrollment
Stable systemic disease
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
LVEF at least 50%
Adequate hematologic, renal, and hepatic function
Life expectancy more than 12 weeks
You may not be if
Progression of systemic disease at Screening
Leptomeningeal disease
History of intolerance or hypersensitivity to study drug
Use of certain investigational therapies within 21 days prior to enrollment
Current anthracycline use
Unwillingness to discontinue ado-trastuzumab emtansine or lapatinib use
Active infection
Pregnant or lactating women
Significant history or risk of cardiac disease
Symptomatic intrinsic lung disease or lung involvement
History of other malignancy within the last 5 years
Clareo Health | A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
